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Abstract
Objective—Functional status at hospital discharge may be a risk factor for adverse events among 
survivors of critical illness. We sought to examine the association between functional status at 
hospital discharge in survivors of critical care and risk of 90-day all-cause mortality after hospital 
discharge.
Design—Single center retrospective cohort study
Setting—Academic Medical Center
Patients—10,343 adults who received critical care from 1997 to 2011 and survived 
hospitalization.
Interventions—None
Measurements and Main Results—The exposure of interest was functional status determined 
at hospital discharge by a licensed physical therapist and rated based on qualitative categories 
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adapted from the Functional Independence Measure. The main outcome was 90-day post hospital 
discharge all-cause mortality. A categorical risk prediction score was derived and validated based 
on a logistic regression model of the function grades for each assessment. In an adjusted logistic 
regression model, the lowest quartile of functional status at hospital discharge was associated with 
an increased odds of 90-day post-discharge mortality compared to patients with independent 
functional status [OR=7.63 (95%CI 3.83, 15.22; P<0.001)]. In patients who had at least seven days 
of physical therapy treatment prior to hospital discharge (N=2,293), the adjusted odds of 90-day 
post-discharge mortality in patients with marked improvement in functional status at discharge 
was 64% less than patients with no change in functional status [OR 0.36 (95%CI 0.24–0.53); 
P<0.001].
Conclusions—Lower functional status at hospital discharge in survivors of critical illness is 
associated with increased post-discharge mortality. Further, patients whose functional status 
improves before discharge have decreased odds of post-discharge mortality.
Introduction
Critical illness is an important public health issues because of the high rate of mortality and 
sizeable healthcare costs. In 2008–2009, there were 4.14 million patients admitted to 
intensive care representing a substantial increase over the prior decade (1–3). In-hospital 
mortality is 12% for patients who receive critical care and can be as high as 30% in those 
with sepsis (4). As critical illness in-hospital mortality has decreased during the last 30 
years, interest in long-term outcomes of intensive care unit (ICU) survivors has deepened. 
ICU survivors have a high mortality rate and often suffer long-term physical impairments, 
profound neuromuscular weakness, exercise limitation, neuropsychological issues, increased 
healthcare utilization and lower quality of life following hospital discharge (5–12).
Early physical therapy in the ICU has historical precedence (13, 14) and has been shown to 
be safe (15–17). Patients on mechanical ventilation who receive early physical therapy have 
improved functional independence (15, 16). Early implementation of a combination of 
sedation interruption, physical therapy and occupational therapy interventions is shown to 
improve functional status at hospital discharge (17). A recent systematic review and meta-
analysis noted that physical therapy in the ICU may be related to improved quality of life, 
better physical function, more ventilator-free days, and shorter hospital and ICU length of 
stay (18). However, despite the benefits, studies show that physical therapy interventions are 
historically underutilized in the ICU (16, 19).
While studies suggest that functional status may be modifiable in the ICU (16, 17, 20–22), to 
date, limited information exists in ICU survivors regarding the association between 
functional status at hospital discharge and adverse events following hospital discharge. We 
hypothesized that poor functional status at hospital discharge would be associated with 
increased mortality during the 90 days following hospital discharge. To explore this 
hypothesis, we performed a single center observational cohort study of 10,343 critically ill 
adults from 1997 to 2011 who had an evaluation by a physical therapist at hospital 
discharge. Further, we investigated whether improvement in functional status during 
hospitalization is associated with improved 90-day mortality following hospital discharge.
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Materials and Methods
Source population and Data Sources
We abstracted patient-level administrative and laboratory data from the Brigham and 
Women’s Hospital (BWH), a 793 bed teaching hospital in Boston, Massachusetts. Data on 
all patients admitted to BWH between November 20, 1997 and April 5, 2011 were obtained 
through the Brigham Integrated Computing System (BICS) (23) and the Research Patient 
Data Registry (RPDR) at Partners HealthCare (24, 25). Approval for the study was granted 
by the Partners Human Research Committee (Institutional Review Board).
Study population
Patients were eligible for study inclusion if they were adults admitted to the Brigham and 
Women’s Hospital as inpatients and received medical or surgical intensive care during their 
hospitalization. During the study period, there were 37,271 individual patients, age ≥18 
years, who were assigned the Current Procedural Terminology code 99291 (critical care, 
first 30–74 minutes) during hospitalization admission. We have previously validated the 
Current Procedural Terminology code 99291 for ICU admission in the RPDR database (26). 
Exclusions included: 118 foreign patients without Social Security Numbers; 1,587 patients 
assigned CPT code 99291 who received care only in the Emergency Room, were not 
admitted and were not assigned a Diagnosis Related Group (DRG); 4,528 patients who died 
as in-patients; and 20,695 patients who did not receive a formal structured evaluation from a 
Physical Therapist within 48 hours of hospital discharge. Thus, the analytic cohort was 
comprised of 10,343 patients whom were evaluated by a Physical Therapist within 48 hours 
of hospital discharge. The derivation cohort consisted of a random selection of 2/3 of the 
analytic cohort (n= 6,895), and the validation cohort comprised the remaining 1/3 of the 
analytic cohort (n= 3,448) (Figure 1).
Exposure of interest and covariates
The exposure of interest was functional status at hospital discharge defined as physical 
function assessed at the time of hospital discharge. Data was obtained from licensed physical 
therapists trained on the determination of physical function based on qualitative categories 
adapted from the functional mobility sub scales of the Functional Independence Measure 
(FIM) (27, 28). The FIM mobility sub scales incorporate transfers (including bed, chair, and 
wheelchair) as well as locomotion (including walking/wheelchair and stairs), and are scored 
on an ordinal scale based on percentage of active patient participation in the selected task 
(27). The adapted scoring system grades patients on a scale of function with six designations 
from independent through dependent for motor tasks assessed, with a determination of not 
applicable used when a patient was either incapable of progressing to the designated task or 
for physical or medical limitations. The six designations were independent, standby assist/
supervision, minimal assist, moderate assist, maximal assist, and total assist (Supplemental 
Table 1). Patients were assessed on bed mobility (roll side to side, supine to sit, sit to 
supine), transfers (sit to stand, stand to sit, bed to chair), and gait (level ambulation, stairs). 
The FIM scoring system is widely used by rehabilitation practitioners across the continuum 
of care and allows for clinicians to follow up and compare functional status throughout the 
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rehabilitation process (29). The physical therapists were not aware of the study hypothesis, 
exposure or outcomes.
Race was either self-determined or designated by a patient representative/healthcare proxy. 
Patient admission ‘type’ was defined as ‘medical’ or ‘surgical’ and incorporates the DRG 
methodology (30). We utilized the Deyo-Charlson Index to assess the burden of chronic 
illness which is well studied and validated (31). Sepsis is defined by the presence of any of 
the following ICD-9-CM codes: 038.0–038.9, 790.7, 117.9, 112.5, or 112.81, three days 
prior to critical care initiation to seven days after critical care initiation, an approach that we 
have validated in our database (32). Using electronic pharmacy records, exposure to 
inotropes and vasopressors was determined for dopamine, dobutamine, epinephrine, 
norepinephrine, phenylephrine, milrinone and vasopressin. Inotropes or vasopressors were 
considered to be present if prescribed three days prior to critical care initiation to seven days 
after critical care initiation (33). Exposure to high dose intravenous glucocorticoids 
following ICU admission was determined for hydrocortisone, methylprednisolone and 
dexamethasone and were considered to be present if prescribed for at least four doses 
following ICU admission (34). Exposure to neuromuscular blocking agents (NMBA) 
following ICU admission was determined for cisatracurium, mivacurium, pancuronium, 
vecuronium, rocuronium and considered to be present if prescribed for at least four doses 
following ICU admission (35).
Number of organs with acute failure was adapted from Martin et.al. (36) and defined by a 
combination of ICD-9-CM and CPT codes relating to acute organ dysfunction (respiratory, 
cardiovascular, renal, hepatic, hematologic, metabolic and or neurologic) assigned from 3 
days prior to critical care initiation to 30 days after critical care initiation (26, 32, 33). Acute 
kidney injury was defined as RIFLE class Injury or Failure occurring between three days 
prior to critical care initiation and seven days after critical care initiation (37). 
Noncardiogenic acute respiratory failure was identified by the presence of ICD-9 codes for 
respiratory failure or pulmonary edema (518.4, 518.5, 518.81, and 518.82) and mechanical 
ventilation (96.7×), excluding congestive heart failure (428.0–428.9) following hospital 
admission (38). For severity of illness risk adjustment, we employed the Acute Organ 
Failure score, an ICU risk-prediction score derived and validated from demographics (age, 
race), patient admission ‘type’ as well as ICD-9-CM code based comorbidity, sepsis and 
number of organs with acute failure covariates which has similar discrimination for 30 day 
mortality as APACHE II (39). Malnutrition was considered to be present if the patient was 
diagnosed by a Registered Dietitian 10 days prior to 2 days after ICU admission with 
nonspecific protein-calorie malnutrition; or specific (mild, moderate or severe) protein-
calorie malnutrition (40, 41).
End points
The primary end point was 90-day all-cause mortality following hospital discharge (33). 
Secondary endpoints included 30 and 365-day all-cause mortality following hospital 
discharge.
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Assessment of Mortality
Vital status was obtained from the Social Security Administration Death Master File which 
has high sensitivity and specificity for mortality (42). We have validated the accuracy of the 
Social Security Administration Death Master File for in-hospital and out-of-hospital 
mortality in the RPDR database (26). 100% of the cohort had at least 90-day follow up after 
hospital discharge. The censoring date was April 6, 2012.
Power calculations
Previously, in a cohort of critically ill patients (n=43,212), we studied post-discharge 
mortality in ICU survivors (33). From these data, we assumed that 90-day post-discharge 
mortality would be 4% higher among the patients with the lowest quartile function 
compared to those the highest quartile function. With an alpha error level of 5% and a power 
of 80%, the sample size required for our primary end point (90-day post-discharge mortality) 
was 852 patients with the lowest quartile of functional status and 852 patients with 
independent functional status.
Derivation and validation of the risk score
A clinical prediction model was created based on a logistic regression model describing the 
risk of 90-day post-discharge mortality as a function of the predictors at discharge [Bed 
Mobility (roll side to side, supine to sit and sit to supine), Transfers (sit to stand, stand to sit 
and bed to chair) and Gait level]. We utilized a random number service that generates 
randomness via atmospheric noise to randomly select of 2/3 of the analytic cohort for the 
derivation cohort and 1/3 of the analytic cohort for the validation cohort (43). The model 
was transformed to a simplified integer-based score, with a score for the scale of function for 
each individual predictor variable [i.e. “independent” for Bed Mobility (roll side to side)] 
assigned by dividing its β-coefficient by the smallest coefficient in the model, multiplying by 
2 and rounding up to the nearest integer (Supplemental Table 2). A risk score was then 
calculated for each patient by summing each individual predictor variable score. 
Subsequently, the population was first divided into quartiles of risk score with the highest 
quartile of functional status then subdivided into independent and patients at low risk. Thus 
the five categories assigned were: independent patients, patients at low risk, patients at 
intermediate risk, patients at high risk and patients at very high risk for death.
Descriptive statistics
Categorical variables were described by frequency distribution, and compared across 
outcome groups using contingency tables and chi-square testing. Continuous variables were 
examined graphically and in terms of summary statistics, and then compared across outcome 
groups using one-way analysis of variance or the Kruskal–Wallis test. For the 90-day post-
discharge mortality model, specification of each continuous covariate (as a linear versus 
categorical term) was adjudicated by the empiric association with the primary outcome using 
Akaike’s Information Criterion. Adjusted odds ratios were estimated by multivariable 
logistic regression models with inclusion of covariate terms thought to plausibly associate 
with both functional status and 90-day post-discharge mortality. We individually tested for 
effect modification by functional status by year of hospital admission, hospital length of 
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stay, neuromuscular blocking agent use, nutritional status, vasopressors/ inotropes, 
glucocorticoid use and metastatic malignancy by adding an interaction term to the 
multivariate models. Further, a multivariable Cox's proportional hazards model was used to 
illustrate post-discharge survival related to functional status. For the time to mortality, we 
estimated the survival curves according to functional status quartile with the Kaplan-Meier 
method and compared the results via the log-rank test.
Performance of the score
The discriminatory ability of the clinical predication model for 90-day post-discharge 
mortality was quantified using the c-statistic. Calibration was assessed using the Hosmer-
Lemeshow χ2 goodness-of-fit test and the accompanying p-value, based on ten subgroups of 
participants and 8 degrees of freedom (44). Bayes information criterion was also used to 
determine global model fit (45). The improvement in model performance was evaluated via 
net reclassification improvement with a cut-point of 50% or integrated discrimination 
improvement (46).
Subanalyses
In patients who had a functional status evaluation at least seven days prior to the discharge 
functional status evaluation we evaluated the association between improved functional status 
and post-discharge mortality. The change in physical therapy score between initial and 
discharge evaluation was categorized in five groups a priori based on risk score points 
distribution noted in the FIM mobility sub scales (specifically Transfers and Bed Mobility) 
between independent, minimal assist and maximal assist scale of function (Supplemental 
Table 2).
In all analyses, p-values are two-tailed and values below 0.05 were considered statistically 
significant. All analyses were performed using STATA 13.1MP statistical software 
(StataCorp LP, College Station, TX).
Results
Survival Analysis and Risk-Scoring System
Significant differences exist between the derivation cohort and the excluded 20,695 patients 
who did not receive a formal structured evaluation from a Physical Therapist (Supplemental 
Table 3). Patient characteristics of the derivation cohort were stratified according to 90-day 
post-discharge mortality (Table 1). The mean age at hospital admission was 63.6 years. Most 
patients were male (54%), white (78%), had a surgically-related DRG (61%). Derivation 
cohort patients were discharged to a care facility (56%), to home care (27%), to home 
without services (10%) or to hospice (0.4%). Factors that were associated with 90-day post-
discharge mortality included higher age, medical patient type, higher Deyo-Charlson Index, 
increased number of organs with acute failure. In addition, 90-day post-discharge mortality 
was heightened with the presence of malignant neoplasm, malnutrition, acute kidney injury, 
or sepsis, as well as an increased hospital length of stay and a higher Acute Organ Failure 
score (Table 1). 30, 90 and 365-day post-discharge mortality rates were 4.5%, 9.8%, and 
20.6%, respectively.
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The patients were divided into five groups on the basis of the functional status risk score 
point distribution, which ranged from 0 to 29 points. Survival estimates for the five groups 
showed different post-discharge mortality rates at 90 and 365 days: independent (0 points), 
low risk (1 to 8 points), intermediate risk (9 to 18 points), high risk (19 to 24 points) and 
very high risk (>24 points) (Table 2).
Small but statistically significant differences in Deyo-Charlson index are present between 
derivation and validation cohorts (Supplemental Table 4). Classification of the derivation 
cohort according to risk score resulted in similar percentages of patients assigned to risk 
groups as in the derivation cohort (Table 2). Further the 90-day post-discharge mortality 
rates for the independent, low, intermediate, high and very high risk groups were similar in 
the derivation and validation cohorts (Table 3). The AUC for the prediction model for 90 day 
post-discharge mortality was 0.673 (95%CI 0.63–0.77) in the derivation cohort and 0.674 
(95%CI 0.65–0.70) in the validation cohort. The prediction model showed good calibration 
in the derivation and validation cohorts (HL χ2 13.3, P= 0.10 and HL χ2 11.1, P= 0.20 
respectively). Thus, the risk score showed good calibration and similar discrimination in the 
derivation and validation cohorts.
Primary Outcome
In the validation cohort, mortality in the 90 days after hospital discharge was higher in 
patients with decreased functional status at hospital discharge. The Kaplan-Meier plot 
(Figure 2) demonstrates survival grouped according to functional status at hospital discharge 
in the cohort and shows a significant difference between the five curves (P< 0.001). The 
odds of 90-day post-discharge mortality in patients with high risk and very high risk 
functional status at discharge were 7.1 and 10.6 fold higher respectively than patients with 
independent functional status (Table 4). Functional status remained a significant predictor of 
the odds of 90-day post-discharge mortality after adjustment for the Acute Organ Failure 
score and gender. The adjusted odds of 90-day post-discharge mortality in patients with high 
risk and very high risk functional status at discharge were 5.4 and 7.6 fold higher 
respectively than patients with independent functional status (Table 4). The adjusted 90-day 
post-discharge mortality model showed good calibration (HL chi-squared 9.62, P = 0.29) 
and discrimination [c-statistic= 0.73 (95%CI 0.70–0.75)]. Further, the hazard ratio of 
mortality adjusted for the Acute Organ Failure score and gender in patients with high risk 
and very high risk functional status at discharge were 2.09 (95% CI 1.65–2.66) and 2.19 
(95% CI 1.73–2.78) respectively relative to patients with independent functional status.
In the validation cohort, there is no significant effect modification of the functional 
status-90-day post-discharge mortality association on the basis of year of hospital admission 
(P-interaction=0.33), hospital length of stay (P-interaction=0.21), neuromuscular blocking 
agent use (P-interaction =0.89), glucocorticoid use (P-interaction=0.70) or nutritional status 
(P-interaction =0.27). Effect modification is present regarding the presence of vasopressors/
inotropes (P-interaction=0.01), and metastatic malignancy (P-interaction<0.001). 
Individually adding a year, vasopressor/inotrope, neuromuscular blocking agent, 
glucocorticoid use or a metastatic malignancy term to the final model does not alter the 
effect size or significance of the change in functional status-90 day post-discharge mortality 
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association (data not shown). Evaluation of the functional status-90 day post-discharge 
mortality association prior to and after 2005 showed similar estimates (Supplemental Table 
5). While patients with and without vasopressor/inotrope or metastatic malignancy present 
have different risk estimates, the directionality and significance of the functional status-post-
discharge mortality association remains.
Secondary Outcome
We evaluated the net reclassification improvement and integrated discrimination 
improvement following inclusion of functional status in a multivariable adjusted model. A 
model adjusted for Acute Organ Failure score and gender showed good calibration (HL χ2 
0.87, P= 0.99) and discrimination for 90-day post-discharge mortality [AUC 0.70 (95%CI 
0.67–0.73)]. The model adjusted for Acute Organ Failure score, gender, and functional 
status risk score showed good calibration and improved discrimination [AUC 0.73 (Table 
3)]. Differences in model discrimination between the models were significant (χ2 18.34, 
P<0.001). Further, with inclusion of functional status risk score to the model adjusted for 
Acute Organ Failure score and gender, the net reclassification improvement (NRI) was 
estimated at 0.039 (P=0.016) and the integrated discrimination improvement (IDI) was 
estimated at 0.024 (P>0.001). The NRI and IDI suggest that including functional status risk 
score results in a small but significant improvement in model performance.
Subanalysis
In patients who had a functional status evaluation at least seven days prior to the discharge 
functional status evaluation we evaluated the association between improved functional status 
and post-discharge mortality. The change in physical therapy score between initial and 
discharge evaluation was categorized in five groups: Marked improvement (>9 points down), 
Intermediate improvement (4 to 9 points down), Modest improvement (1 to 3 points down), 
No improvement (0 points) and Worse functional status (increase in points). Differences 
were present among the change in functional status groups (Supplemental Table 6).
In a subset of analytic cohort patients who had functional status assessed at least seven days 
prior to discharge and at discharge (N=2,293), we analyzed the association between change 
in functional status and 90-day post-discharge mortality. Mortality 90 days following 
hospital discharge was lower in patients whose functional status improved prior to hospital 
discharge. The odds of 90-day post-discharge mortality in patients with marked or 
intermediate improvement in functional status at discharge was 64% and 50% respectively 
less than patients with no change in functional status after adjustment for the Acute Organ 
Failure score, gender and the number of days between initial and discharge physical therapy 
assessment (Table 5). When change in functional status was a modeled as a continuous 
exposure, the odds of adjusted 90 day post-discharge mortality showed a relative decrease of 
6% for every 1 unit decrease in functional status risk score [OR 0.94 (95%CI 0.92–0.96; 
P<0.001)].
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Discussion
In our cohort of adult survivors of critical care, we sought to characterize the relationship 
between functional status at hospital discharge and subsequent mortality. Our data suggests 
that there is a heightened risk of 90-day post-discharge mortality in ICU survivors with 
decreased functional status. Our work highlights the importance of functional status in risk 
assessment and suggests that functional status may be a modifiable risk factor for outcomes 
of ICU survivors.
In ICU survivors, long-term functional impairment is a common complication (47). Patients 
with pre-ICU functional disability have heightened mortality in the year following ICU 
admission (48). Hospitalization is associated with decline in functional status and 
independence (49, 50). Skeletal muscle atrophy can be demonstrated with more than 72 
hours of immobilization in healthy subjects (51). With prolonged bed rest, older adults show 
larger losses of muscle mass and strength relative to young adults (52). In the critically ill, 
muscle mass loss and decreased strength are common complications (53–56). Pre-ICU 
functional disability in basic, instrumental, and mobility activities is associated with a 
heightened mortality in the year following ICU admission (48). Further, self-perceived 
functional status of ICU survivors 6 and 12 months following hospital discharge is 
associated with self-perceived basal functional status determined at ICU admission (57). 
Additionally, frailty is an important driver of ICU survivorship and out of hospital outcomes 
(54, 58) and likely influences functional status at hospital discharge. Frailty closely 
correlates with ageing (59) and functional status changes due to critical illness likely differ 
by age (48).
ICU-acquired weakness (60) is associated with multiple organ failure, hyperglycemia, 
corticosteroids, neuromuscular blockers, decreased nutrient intake, malignancy, muscle 
wasting from catabolism, physical inactivity and immobilization (61–67). Decreased 
measured strength in critically ill patients is shown to be associated with adverse in-hospital 
outcomes (68). Importantly, early rehabilitation in the ICU is demonstrated to be safe and 
can improve functional status (15–17, 22). In critical illness survivors, exercise training 
during hospitalization improved functional capacity and muscle force measured at hospital 
discharge (22).
The potential limitations of this study are related to the observational design with inherent 
biases related to confounding, potential reverse causation, and the lack of a randomly-
distributed exposure. Ascertainment bias may be present as the study cohort had functional 
status measured for reasons that may be absent in other ICU patients. The study was 
performed in a single Boston tertiary care hospital and thus the results may not be 
generalizable to other acute care settings. Residual confounding may be present despite 
adjustment for multiple potential confounders. While the established scales of functional 
status were utilized (27, 28), these measures are subjective and potentially subject to 
misclassification. We are also unable to adjust for some variables that can alter functional 
status, including immobility and catabolism. Further, we do not have objective measures of 
sacropenia (69) or electrophysiological features of possible critical illness polyneuropathy or 
critical illness myopathy (70).
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The present study has several strengths and is unique in that it incorporates functional status 
directly measured by a physical therapy practitioner to investigate 90-day post-discharge 
mortality in ICU survivors. Long term post-discharge mortality is previously validated in the 
RPDR database under study (26). We have sufficient statistical power to detect a clinically 
relevant difference in 90-day post-discharge mortality. In addition, we utilized validated 
assessments of ICU admission (26), comorbidities (37), severity of illness (39), acute kidney 
injury (37) and sepsis (32).
Conclusions
In this single center study of 10,343 hospitalized patients, we demonstrate that decreased 
functional status at hospital discharge is associated with increased mortality following 
discharge. Further, an improvement in functional status prior to hospital discharge is 
associated with improved post-discharge mortality. Though our study cannot determine 
causation, our clinical data linking improved functional status with better clinical outcomes 
supports the rationale for physical therapy in ICU survivors before hospital discharge.
Our data supports that the performance of functional status evaluation at discharge can 
identify ICU survivors at high risk for subsequent adverse events. Early performance of 
functional status evaluation in combination with screening for frailty following ICU 
admission may identify patients who are at highest risk for functional decline and those who 
may most benefit from physical therapy. As ICU survivors transition to the outpatient 
setting, it is important to screen for impairment of physical function in addition to cognitive 
function and nutritional status, and align advance care planning appropriately. The emphasis 
of strength maintenance or improvement during hospitalization and following hospital 
discharge should be part of a multidisciplinary effort to maximize the potential for recovery 
in ICU survivors.
Supplementary Material
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Figure 1. Flow Chart
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Figure 2. Time-to-Event curves for post discharge mortality in validation cohort (N=3,448)
Note: Unadjusted all-cause mortality rates were calculated with the use of the Kaplan-Meier 
methods and compared with the use of the log-rank test. Categorization of risk groups is per 
the primary analysis. The global comparison log rank p value is <0.001.
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Table 5
Risk of Death at 90 days and 1 Year after Discharge According to Functional Status Improvement. (N= 2,293)
Functional Status Improvement Category No. (%) Death 90 d
OR (95% CI)
P
Death 365 d
OR (95% CI)
P
Marked 494 (22) 0.36 (0.24, 0.53)
<0.001
0.47 (0.36, 0.63)
<0.001
Intermediate 541 (24) 0.50 (0.35, 0.71)
<0.001
0.60 (0.46, 0.78)
<0.001
Modest 259 (11) 0.69 (0.41, 1.18)
0.18
0.87 (0.58, 1.32)
0.52
No change 531 (23) 1.00 (Referent)a 1.00 (Referent)a
Worsened Functional Status 468 (20) 1.05 (0.76, 1.44)
0.77
1.06 (0.81, 1.38)
0.66
Note: Patients who did not have a functional status evaluation at least seven days prior to the discharge functional status evaluation were excluded. 
The change in physical therapy score was categorized in five groups: Marked improvement (>9 points down), Intermediate improvement (4 to 9 
points down), Modest improvement (1 to 3 points down), No improvement (0 points) and Worse functional status (increase in points). Functional 
status is scored on a scale of 0–29 points with 0 points being independent and 29 points having the poorest functional status. Estimates adjusted for 
Acute Organ Failure score, gender and the number of days between initial and discharge physical therapy assessment
a
. Referent in each case is no change in functional status.
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